Precision Oncology In Northern KZN: Personalised, World-Class Cancer Care

This article is produced in partnership with Melna Oncology Centre as part of a paid educational collaboration.

Picture this: Frans, a 58-year-old farmer near Newcastle, battles a persistent cough that refuses to go away. Across the region, Lerato, a 45-year-old nurse in Vryheid, notices changes in her breast during a self-examination. Both receive cancer diagnoses — lung for Frans, breast for Lerato.

Not long ago, fear would have sent them packing for Durban’s crowded clinics or Pretoria’s specialist wards, convinced that only “big city” doctors could help.

But the rise of precision oncology is rewriting that story.

This revolution in cancer care delivers smart, gene-guided treatments tailored to each patient — the same world-class protocols used internationally, now available closer to home.

At Melna Oncology Centre in Newcastle, patients like Frans and Lerato can now access advanced, individualised treatments without the 500 km journey. It’s keeping families together, spirits lifted, and healing local. This isn’t elite care for a select few — it’s everyday hope grounded in science that’s levelling the playing field.

Cancer remains a heavy burden across South Africa, with over 100,000 new cases diagnosed each year, and KwaZulu-Natal bears its share. According to the National Institute for Communicable Diseases (NICD) cancer registry (2023–2025), prostate, breast, colorectal, lung, and cervical cancers remain the most commonly reported across the country. Current national estimates suggest that approximately one in seven South Africans will develop cancer during their lifetime.

In Northern KZN, colorectal cancer tops the list for men, while breast cancer leads for women, often appearing in their 40s and 50s — a trend fuelled by processed foods, lifestyle shifts, and environmental factors.

The good news? Precision oncology is transforming treatment by matching therapies to the unique profile of each tumour. Instead of relying solely on broad chemotherapy approaches, oncologists can now use targeted medicines that focus on cancer cells while sparing more healthy tissue. Advances such as liquid biopsies are also emerging, offering the potential to detect tumour signals earlier through minimally invasive blood tests.

At the heart of this revolution is genomic profiling — a biopsy or specialised blood test that reads a tumour’s genetic code much like a barcode, helping oncologists identify the drivers behind each cancer.

This leap forward includes the development of AI-supported diagnostic tools and multi-cancer early detection tests, which are showing promising results in identifying tumour signals from a single blood sample. Early trials report high accuracy for several cancers, particularly in advanced research settings, and may significantly shorten the time between suspicion and diagnosis as these technologies continue to evolve.

For Lerato, whose cancer may be HER2-positive (seen in roughly 15–20% of breast cancer cases), targeted therapies such as trastuzumab-deruxtecan offer a more precise approach. Clinical studies show that these medicines can improve outcomes compared to traditional chemotherapy by focusing treatment directly on HER2-driven tumour cells.

Frans’ lung tumour could reveal an EGFR mutation — more common in non-smokers — which would make him a candidate for osimertinib. This once-daily targeted therapy has demonstrated the ability to slow tumour progression with fewer side effects than older treatments and has been shown in international studies, including those cited by the American Association for Cancer Research (AACR), to extend survival for many patients with EGFR-mutated lung cancer.

Meanwhile, prostate cancer patients are seeing major benefits from PSMA-targeted radiotheranostics — a modern treatment that locates PSMA-expressing tumour cells with high precision and delivers focused radiation directly to them.

Clinical trials have shown meaningful tumour shrinkage in advanced cases, providing another effective option for patients who previously had limited alternatives.

These developments reflect a broader shift in oncology. Many of the innovations once considered experimental — from targeted therapies to advanced imaging and genomic testing — are already being integrated into real-world cancer care. Patients are beginning to experience the practical impact of these advances today, not in some distant future.

According to World Economic Forum (WEF) published commentary, personalised cancer vaccines that teach the immune system to recognise tumour-specific antigens are now in Phase 3 trials for melanoma and being explored for lung cancer

Furthermore, global genomics research continues to accelerate the development of personalised cancer care.

IQVIA’s 2025 genomics report highlights how rapidly expanding sequencing initiatives — together with declining sequencing costs and improved data-analytics platforms — are helping broaden access to advanced genomic technologies in low- and middle-income regions.

At the same time, next-generation tools such as single-cell sequencing are giving oncologists deeper insight into tumour diversity and resistance patterns, while emerging AI-driven models are being developed to support more accurate treatment selection. Although the exact impact varies by cancer type, these technologies are steadily reducing diagnostic uncertainty and improving the ability to match patients with the most effective therapies sooner.

For many patients, these advances translate into more tolerable treatment journeys, with targeted therapies and precision-guided approaches often producing fewer side effects than traditional chemotherapy. In many cases, this means milder symptoms — such as manageable nausea or fatigue — and a quicker return to daily routines compared to the broader, non-specific treatments of the past.

What makes this possible is standardisation. Updated international guidelines from the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO) set out detailed pathways for testing, treatment selection, and follow-up in modern cancer care.

These evidence-based protocols are routinely used by oncologists across South Africa, ensuring clinical decisions align with globally recognised best practice.

In addition, national bodies such as the NICD and South African oncology groups reference these same standards when developing local frameworks and treatment pathways, helping maintain consistency across regions. In practical terms, this means that a HER2-positive breast cancer patient receiving therapy in Newcastle follows the same evidence-based protocol as one in Durban or Pretoria, aligned with what is expected in major international centres — even if resources may differ between facilities.

At Melna Oncology Centre, this consistency comes to life through comprehensive services including targeted therapy, immunotherapy, radiotherapy planning , and palliative care — all coordinated from Suite 12, Medicare Medical Centre, 85 Bird Street, Newcastle.

While radiotherapy is delivered at centres in Hilton or Pietermaritzburg due to the absence of a local LINAC machine, all treatment planning and oversight remain under Dr Thandeka Buthelezi-Zulu’s direct management. Patients are supported with accommodation during treatment, and all chemotherapy and follow-up care occur locally — maintaining continuity, safety, and convenience without compromising clinical standards.

Sadly, a lack of awareness still leads many Northern KZN residents to travel long distances for cancer care — often worsening outcomes due to treatment delays, travel constraints, and added stress. Yet there is no need.

Melna Oncology Centre’s fully accredited (ICON and SAOC) chemotherapy unit and precision-guided treatment pathways ensure premium care right here at home.

As cancer patterns evolve in Northern KZN, oncologists are increasingly relying on genomic tools to match patients with the most effective treatments.

This shift is particularly meaningful for communities that have historically faced barriers to specialist care.

“The rise in breast, lung, and colorectal cancers in Northern KZN has led us to prioritise genomic testing for tailored treatment plans. Identifying specific mutations allows us to offer targeted therapies, improving outcomes and reducing unnecessary side effects. One patient with advanced EGFR-mutated lung cancer benefited greatly from genomic testing, receiving a targeted drug(Osimertinib) that significantly extended her life. Staying local meant timely access to care and support, highlighting the importance of accessible, advanced oncology services in our region,” states Dr Thandeka Buthelezi-Zulu.

This alignment between modern cancer trends and personalised treatment ensures that patients in small towns are not left behind as global oncology advances. Consistency in cancer care is especially important in regions where many still assume that major cities offer inherently superior treatment. Today’s internationally recognised guidelines give oncologists in South Africa a shared evidence base, making comparable standards of care possible across different settings.

As Dr Thandeka Buthelezi-Zulu explains, “The ESMO and NCCN guidelines support consistency in precision cancer treatment at Melna Oncology Centre by providing globally recognised, evidence-based protocols that are used across South Africa, including major centres in Durban and Pretoria. While rural areas may face resource constraints, Melna addresses these through tailored patient support, outreach, and strict adherence to updated guidelines to ensure equitable, high-quality care.”

In practice, this means treatment decisions are guided by the same scientific evidence, whether a patient is in Newcastle or a metropolitan oncology unit, even if the specific facilities or equipment differ.

Alongside advanced therapies, patients often ask what they can do personally to improve their treatment journey. Evidence shows that lifestyle, mental health, and supportive care play a significant role. “For patients newly diagnosed with common cancers like breast or lung, key advice during precision treatment includes maintaining a healthy weight through balanced nutrition, engaging in regular moderate exercise, managing side effects with medication and supportive care, and addressing emotional well-being with counselling and support. These steps optimise treatment tolerance and outcomes,” states the doctor.

These practical adjustments can meaningfully support patients undergoing precision-guided therapies. Access is not simply a matter of distance — it affects continuity of care, treatment success, and quality of life. For many families, staying close to home plays an important role in maintaining stability and emotional strength during treatment.

“Accessing precision oncology locally in Northern KZN is vital to minimise travel-related delays, costs, and disruption. It alleviates emotional stress and social isolation by keeping patients near family support networks, enhancing adherence to treatment and overall well-being. Local care ensures timely, individualised therapy within a familiar environment,” explains Dr Thandeka Buthelezi-Zulu.

This approach transforms cancer care from an overwhelming logistical challenge into a manageable, humane experience.

In addition, the pace of oncology innovation continues to accelerate, with liquid biopsies and AI set to redefine early detection and treatment planning. Diving into this, Dr Thandeka Buthelezi-Zulu underscores that, “Advances in liquid biopsies and AI will transform precision care at Melna by enabling earlier, non-invasive cancer detection and personalised treatment plans. These technologies will enhance real-time monitoring and predictive accuracy, improving patient outcomes and streamlining therapy adjustments for more targeted, effective oncology care in 2026.”

As per the doctor, these developments will strengthen Melna Oncology Centre’s ability to deliver forward-looking, globally aligned care for Northern KZN. Therefore, please remember: if cancer knocks, or you’re supporting someone who’s fighting, know this — answers are nearby. Precision oncology isn’t a destination; it’s a decision.

To learn more about screenings, symptoms, or treatment options, visit www.melnaoncology.co.za or call 034 317 3460 to book an appointment with Dr Thandeka Buthelezi-Zulu.

Healing starts where you stand — let’s make it happen, together.

Be sure to read, What Is Type 5 Diabetes? Understanding the Newly Recognised Form of Malnutrition-Related Diabetes, if you missed it.